Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00179660
Status:
COMPLETED
Last Update Posted:
2016-01-21
First Post:
2005-09-13
Brief Title:
Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkins Lymphoma NHL
Sponsor:
Celgene Corporation
Organization:
Celgene
Study Overview
Official Title:
A Phase II Multicenter Single-Arm Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide Revlimid CC-5013 In Subjects With Relapsed Or Refractory Aggressive Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the activity of lenalidomide in relapsed or refractory aggressive NHL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None